TLDR
- Merus (MRUS) receives consensus “Buy” rating from 16 analysts with average price target of $86
- BofA raises price target to $92 from $70 following strong Phase 2 trial results
- Petosemtamab combo therapy achieves 79% survival rate in head and neck cancer patients
- Stock opened at $55.14 with market cap of $3.82 billion and year-to-date high of $61.28
- Recent earnings missed estimates but revenue exceeded expectations at $26.49 million
Merus stock is getting serious attention from Wall Street analysts after the biotech company delivered impressive cancer treatment data. The company now holds a consensus “Buy” rating from 16 analysts covering the stock.
The average price target sits at $86, with individual targets ranging from $75 to $110. HC Wainwright maintains an $85 target while BMO Capital Markets leads the pack at $110.
Strong Trial Results Drive Optimism
The excitement stems from Merus’ Phase 2 trial results for petosemtamab combined with pembrolizumab. The treatment targets first-line head and neck squamous cell carcinoma patients.
The trial hit a 12-month objective survival rate of 79% across the full patient group. This number crushes historical benchmarks for pembrolizumab alone, which typically delivers 50% to 59% survival rates.
BofA analysts were particularly impressed by these results. They had previously indicated that anything in the 50% to 60% range would be considered good data.
The interim data presented at the ASCO Annual Meeting showed even more promise. Among 43 evaluable patients, the treatment achieved a 63% overall response rate.
This included 6 complete responses and 21 partial responses. The median progression-free survival reached 9 months.
Responses occurred across various PD-L1 levels, showing the treatment’s broad potential. At the data cutoff, 14 responding patients remained on treatment.
Stock Performance and Financial Picture
Merus shares opened at $55.14 on Tuesday with a market cap of $3.82 billion. The stock has traded between $33.19 and $61.28 over the past year.
The company’s 50-day moving average sits at $42.88, while the 200-day average is $43.42. The stock carries a beta of 0.94 and trades at a PE ratio of -13.96.
Recent earnings showed mixed results. Merus reported a loss of $1.40 per share, missing consensus estimates of $1.17.
However, revenue came in at $26.49 million, well above the expected $7.82 million. The company maintains a negative return on equity of 38.89% and a negative net margin of 680.61%.
Analysts expect Merus to post -3.85 earnings per share for the current year. Institutional investors own 96.14% of the company’s stock.
Several institutions have increased their positions recently. KBC Group boosted its stake by 4,583.6% in the fourth quarter.
TimesSquare Capital Management increased its holding by 21.6%, now owning 331,195 shares worth $13.927 million. State of New Jersey Common Pension Fund also raised its stake by 29%.
BofA’s price target increase to $92 from $70 reflects growing confidence in the petosemtamab program. The analysts believe the combination therapy could become a best-in-class treatment for head and neck cancer patients.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
